BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2377

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage ; volume:21 ; number:1 ; day:12 ; month:5 ; year:2021 ; pages:1-11 ; date:12.2021
BMC neurology ; 21, Heft 1 (12.5.2021), 1-11, 12.2021

Creator: Wang, Wei
Wang, Maode
Jiang, Haitao
Wang, Tuo
Da, Rong

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12883-021-02224-6

URN: urn:nbn:de:101:1-2021091219233182409517

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wang, Wei
Wang, Maode
Jiang, Haitao
Wang, Tuo
Da, Rong
SpringerLink (Online service)

Other Objects (12)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Related objects

Reset password